QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
QQQ   309.75 (+1.19%)
AAPL   158.93 (+0.70%)
MSFT   277.66 (+1.97%)
META   204.28 (+2.24%)
GOOGL   105.60 (+2.16%)
AMZN   98.71 (+0.01%)
TSLA   192.22 (+0.56%)
NVDA   271.91 (+2.73%)
NIO   9.27 (+1.98%)
BABA   86.52 (+3.43%)
AMD   100.28 (+2.77%)
T   18.46 (+0.38%)
F   11.42 (-0.52%)
MU   61.34 (+5.45%)
CGC   1.91 (+1.60%)
GE   91.59 (+2.23%)
DIS   95.83 (+0.98%)
AMC   4.47 (+3.00%)
PFE   40.18 (+0.42%)
PYPL   72.56 (-2.39%)
NFLX   320.37 (+9.01%)
NASDAQ:GRTS

Gritstone bio - GRTS Competitors

$2.46
-0.02 (-0.81%)
(As of 03/23/2023 12:00 AM ET)
Add
Compare
Today's Range
$2.39
$2.55
50-Day Range
$2.13
$3.45
52-Week Range
$1.71
$5.85
Volume
336,751 shs
Average Volume
780,459 shs
Market Capitalization
$215.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

GRTS vs. IPSC, JSPR, MOLN, OCGN, GNFT, CABA, FENC, ARYD, IPHA, and OPT

Should you be buying Gritstone bio stock or one of its competitors? The main competitors of Gritstone bio include Century Therapeutics (IPSC), Jasper Therapeutics (JSPR), Molecular Partners (MOLN), Ocugen (OCGN), Genfit (GNFT), Cabaletta Bio (CABA), Fennec Pharmaceuticals (FENC), ARYA Sciences Acquisition Corp IV (ARYD), Innate Pharma (IPHA), and Opthea (OPT). These companies are all part of the "biological products, except diagnostic" industry.

Gritstone bio vs.

Century Therapeutics (NASDAQ:IPSC) and Gritstone bio (NASDAQ:GRTS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, community ranking, risk, profitability, media sentiment, valuation and dividends.

Century Therapeutics has a beta of 0.69, meaning that its stock price is 31% less volatile than the S&P 500. Comparatively, Gritstone bio has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500.

Gritstone bio has higher revenue and earnings than Century Therapeutics. Gritstone bio is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Century Therapeutics$5.20 million40.51-$130.93 million-$2.28-1.56
Gritstone bio$19.94 million10.99-$119.69 million-$1.33-1.88

35.8% of Century Therapeutics shares are owned by institutional investors. Comparatively, 48.1% of Gritstone bio shares are owned by institutional investors. 10.3% of Century Therapeutics shares are owned by insiders. Comparatively, 4.5% of Gritstone bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Gritstone bio has a net margin of -600.09% compared to Century Therapeutics' net margin of -2,518.41%. Century Therapeutics' return on equity of -38.02% beat Gritstone bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Century Therapeutics -2,518.41% -38.02% -25.17%
Gritstone bio -600.09% -72.52% -52.99%

In the previous week, Century Therapeutics had 22 more articles in the media than Gritstone bio. MarketBeat recorded 27 mentions for Century Therapeutics and 5 mentions for Gritstone bio. Gritstone bio's average media sentiment score of 0.64 beat Century Therapeutics' score of 0.30 indicating that Gritstone bio is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Century Therapeutics
1 Very Positive mention(s)
2 Positive mention(s)
8 Neutral mention(s)
5 Negative mention(s)
0 Very Negative mention(s)
Neutral
Gritstone bio
0 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Century Therapeutics presently has a consensus price target of $19.00, suggesting a potential upside of 433.71%. Gritstone bio has a consensus price target of $5.00, suggesting a potential upside of 100.00%. Given Century Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Century Therapeutics is more favorable than Gritstone bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Century Therapeutics
0 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.90
Gritstone bio
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

Gritstone bio received 113 more outperform votes than Century Therapeutics when rated by MarketBeat users. Likewise, 68.56% of users gave Gritstone bio an outperform vote while only 57.14% of users gave Century Therapeutics an outperform vote.

CompanyUnderperformOutperform
Century TherapeuticsOutperform Votes
20
57.14%
Underperform Votes
15
42.86%
Gritstone bioOutperform Votes
133
68.56%
Underperform Votes
61
31.44%

Summary

Century Therapeutics beats Gritstone bio on 10 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GRTS vs. The Competition

MetricGritstone bioBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$219.15M$2.66B$4.34B$5.82B
Dividend YieldN/A2.26%2.39%4.45%
P/E Ratio-1.882.0290.8511.46
Price / Sales10.99163.073,525.3957.28
Price / CashN/A15.1826.80101.17
Price / Book1.222.614.454.94
Net Income-$119.69M$67.29M$115.21M$190.76M
7 Day Performance-3.47%-2.80%-2.52%-1.40%
1 Month Performance-1.57%2.85%-6.60%-6.87%
1 Year Performance-42.92%-24.96%-16.12%-18.39%

Gritstone bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IPSC
Century Therapeutics
2.1406 of 5 stars
$3.56
-5.3%
$19.00
+433.7%
-70.9%$210.65M$5.20M-1.56170Analyst Report
Analyst Revision
News Coverage
JSPR
Jasper Therapeutics
2.287 of 5 stars
$1.92
-3.5%
$6.21
+223.6%
-46.4%$210.01MN/A-1.8625News Coverage
MOLN
Molecular Partners
1.6875 of 5 stars
$5.80
-2.7%
$8.00
+37.8%
-72.2%$209.28M$198.70M0.00163
OCGN
Ocugen
1.6382 of 5 stars
$0.91
-4.2%
$4.80
+427.0%
-76.3%$206.22M$42.62M-2.4056
GNFT
Genfit
1.7347 of 5 stars
$4.10
+1.0%
$7.00
+70.6%
+3.9%$204.46M$101.25M0.00122
CABA
Cabaletta Bio
2.2152 of 5 stars
$7.49
-3.1%
$14.17
+89.1%
+230.0%$234.74MN/A-4.1453Analyst Report
Analyst Revision
FENC
Fennec Pharmaceuticals
1.6771 of 5 stars
$7.57
-5.3%
$14.83
+95.9%
+24.7%$199.92M$170,000.00-9.23N/AUpcoming Earnings
High Trading Volume
ARYD
ARYA Sciences Acquisition Corp IV
0 of 5 stars
$10.32
+0.2%
N/A+5.6%$198.04MN/A0.003Positive News
IPHA
Innate Pharma
0 of 5 stars
$3.03
-1.0%
$8.90
+193.7%
-9.6%$243.04M$29.23M0.00215News Coverage
OPT
Opthea
1.8271 of 5 stars
$4.20
flat
$21.00
+400.0%
-30.8%$245.29M$90,000.000.002,021
This page (NASDAQ:GRTS) was last updated on 3/23/2023 by MarketBeat.com Staff